Why Mirum Pharmaceuticals, Inc. (MIRM) stock moved
Mirum Pharmaceuticals, Inc. (MIRM) shares climbed 5.7% to $86.01 as of October 9, 2026, a significant gain from the prior close of $81.35. BestStocks flagged the session as a major change for MIRM. Below, we break down what changed for MIRM, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
MIRM climbed 5.7% to $86.01
RBC Capital raised its price target on MIRM from $135 to $155 on October 8, maintaining an Outperform rating, citing growing confidence in Mirum's expanded pipeline. The stock rose 6.15% to $86.35 on normal volume (1.01x average). The catalyst aligns with two near-term milestones: the October 2026 commercial launch of Atebrioz for fibrodysplasia ossificans progressiva (FOP), with revenues expected in early 2027, and late-September positive Phase 3 data for brelovitug in chronic hepatitis delta virus (HDV). Atebrioz launch progress and early revenue data in Q4 2026–Q1 2027; Mirum earnings on November 3, 2026 (consensus: –$0.53 EPS); any additional regulatory or clinical updates on brelovitug for HDV.
What it means for Mirum Pharmaceuticals, Inc. investors
For Mirum Pharmaceuticals, Inc. investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Material positive event; Strong 5.7% price move. Weighing against that: Mirum Pharmaceuticals shares fell 5.85% to $93.04 as investors weigh regulatory uncertainties ahead of a September 26 FDA decision on zilurgisertib for FOP and recent FDA requests for additional Phase 3 clarity on volixibat, according to the web_catalyst synthesis; New SEC filing — review for material disclosures. Wall Street's consensus price target sits at $149.10, implying +73.4% upside from $86.01. BestStocks rates the overall signal quality medium (62/100). With earnings roughly 25 days out, the next report is the most likely near-term test of the move.
MIRM price reaction
MIRM last traded at $86.01, up $4.66 (+5.73%) from the previous close of $81.35. The session traded on 1.5× average volume (normal), so participation was unremarkable.
Bullish and bearish analyst opinions on Mirum Pharmaceuticals, Inc. (MIRM)
The consensus analyst price target on Mirum Pharmaceuticals, Inc. (MIRM) is $149.10, 73.4% above the recent $86.01. Over the past 90 days analysts logged 0 upgrades, 9 maintains, and 0 downgrades. Here is how the bullish and bearish cases on MIRM line up.
The bullish case
- Wall Street's consensus price target of $149.10 implies +73.4% upside from $86.01.
- The Street's most bullish target is $195.00 (+126.7%).
- Material positive event.
- Strong 5.7% price move.
- Mirum Pharmaceuticals, Inc. (MIRM) moved +5.49% from $95.41 to $100.65 on 2026-08-07.
The bearish case
- Mirum Pharmaceuticals shares fell 5.85% to $93.04 as investors weigh regulatory uncertainties ahead of a September 26 FDA decision on zilurgisertib for FOP and recent FDA requests for additional Phase 3 clarity on volixibat, according to the web_catalyst synthesis.
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Oct 9, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for MIRM
In-depth MIRM event analyses
Frequently asked questions about MIRM
Why did Mirum Pharmaceuticals, Inc. (MIRM) stock move?
MIRM climbed 5.7% to $86.01. The move coincided with the context summarized above, though no single company-specific catalyst was independently confirmed.
How much did MIRM stock rise?
MIRM gained 5.73% ($4.66) versus the prior close of $81.35, last trading at $86.01 on 1.5× average volume.
When is Mirum Pharmaceuticals, Inc.'s next earnings date?
MIRM's next earnings report is estimated for 2026-11-03 — about 25 days away.
What is the analyst price target for MIRM?
The consensus analyst price target for MIRM is $149.10, about 73.4% above the current $86.01. Over the past 90 days, analysts recorded 0 upgrades, 9 maintains, and 0 downgrades.
How BestStocks tracks MIRM
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared MIRM-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for MIRM, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of October 9, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.